Page last updated: 2024-10-27

fluorouracil and Exanthem

fluorouracil has been researched along with Exanthem in 23 studies

Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.

Research Excerpts

ExcerptRelevanceReference
"Lapatinib and capecitabine (L-CAP) is effective in HER-2 positive patients with metastatic breast cancer (MBC)."9.19Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine. ( Dranitsaris, G; Lacouture, ME, 2014)
"Inoperable biliary tract cancer patients were treated with the combination of gemcitabine (1000 mg/m(2) on day 1 and 8), capecitabine (1300 mg/m(2)/d on day 1-14) and weekly cetuximab (400mg/m(2) loading and 250 mg/m(2) maintenance dose) in 21-d cycles until progression or the appearance of intolerable side-effects."9.17Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study. ( Budai, B; Ganofszky, E; Hitre, E; Horváth, Z; Juhos, E; Láng, I; Nagy, T; Rubovszky, G; Szabó, E; Szentirmay, Z, 2013)
"This study was designed to investigate the efficacy and safety of the epidermal growth factor receptor (EGFR) inhibitor cetuximab combined with irinotecan, folinic acid (FA) and two different doses of infusional 5-fluorouracil (5-FU) in the first-line treatment of EGFR-detectable metastatic colorectal cancer."9.14Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. ( Brezault, C; Cals, L; Husseini, F; Loos, AH; Nippgen, J; Peeters, M; Raoul, JL; Rougier, P; Van Laethem, JL, 2009)
" He suffered from rash and neutropenia after multiple chemotherapy sessions including oxaliplatin, 5-fluorouracil (5- FU), and calcium folinate injection (CF) which are called FOLFOX regimen for short."7.96Rash and neutropenia after the administration of oxaliplatin and 5-fluorouracil plus calcium folinate injection: a case report. ( Huang, J; Huang, Z; Jiang, C; Liu, Z; Zheng, W; Zhu, X, 2020)
"Lapatinib and capecitabine (L-CAP) is effective in HER-2 positive patients with metastatic breast cancer (MBC)."5.19Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine. ( Dranitsaris, G; Lacouture, ME, 2014)
"Inoperable biliary tract cancer patients were treated with the combination of gemcitabine (1000 mg/m(2) on day 1 and 8), capecitabine (1300 mg/m(2)/d on day 1-14) and weekly cetuximab (400mg/m(2) loading and 250 mg/m(2) maintenance dose) in 21-d cycles until progression or the appearance of intolerable side-effects."5.17Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study. ( Budai, B; Ganofszky, E; Hitre, E; Horváth, Z; Juhos, E; Láng, I; Nagy, T; Rubovszky, G; Szabó, E; Szentirmay, Z, 2013)
"This study was designed to investigate the efficacy and safety of the epidermal growth factor receptor (EGFR) inhibitor cetuximab combined with irinotecan, folinic acid (FA) and two different doses of infusional 5-fluorouracil (5-FU) in the first-line treatment of EGFR-detectable metastatic colorectal cancer."5.14Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. ( Brezault, C; Cals, L; Husseini, F; Loos, AH; Nippgen, J; Peeters, M; Raoul, JL; Rougier, P; Van Laethem, JL, 2009)
"This phase I study was conducted to establish the dose-limiting toxicities and maximum-tolerated dose of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in combination with FOLFIRI, a standard regimen of irinotecan, leucovorin, and infusional 5-fluorouracil (5-FU) in patients with advanced colorectal cancer."5.11Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities. ( Donehower, RC; Grouleff, P; Hidalgo, M; Kelley, SK; Laheru, DA; Lum, BL; Messersmith, WA; Ramies, DA; Rogers, T; Senzer, NN, 2004)
" He suffered from rash and neutropenia after multiple chemotherapy sessions including oxaliplatin, 5-fluorouracil (5- FU), and calcium folinate injection (CF) which are called FOLFOX regimen for short."3.96Rash and neutropenia after the administration of oxaliplatin and 5-fluorouracil plus calcium folinate injection: a case report. ( Huang, J; Huang, Z; Jiang, C; Liu, Z; Zheng, W; Zhu, X, 2020)
"Bevacizumab (Avastin) in combination with intravenous 5-fluorouracil-based chemotherapy as first-line as well as second-line treatment of metastatic colorectal cancer improves survival."3.73Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response. ( Gotlib, V; Khaled, S; Lapko, I; Mar, N; Saif, MW, 2006)
"Acne-like skin rash is a frequently occurring adverse event associated with drugs against the epidermal growth factor receptor."2.87EVITA-a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity. ( Al-Batran, SE; Ettrich, TJ; Feustel, HP; Heeger, S; Hofheinz, RD; Homann, N; Kripp, M; Lorenzen, S; Merx, K; Ocvirk, J; Schatz, M; Schulte, N; Schulz, H; Tetyusheva, M; Trojan, J; Vlassak, S, 2018)
"Cetuximab-induced skin rash Gd3+ occurs in ≥16% patients (pts) (Heinemann et al."2.84Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care. ( Boller, E; Dingeldein, G; Ehscheidt, P; Flohr, T; Galle, PR; Geer, T; Göhler, T; Hebart, H; Heike, M; Indorf, M; Josten, KM; Karthaus, M; Lang, C; Moehler, M; Neise, M; Rudi, J; Schimanski, CC; Schmittel, A; Staib, F; Wierecky, J; Wörns, MA, 2017)
"Lapatinib was administered at doses ranging from 1000 to 1500 mg/day as monotherapy (n=928) or in combination with paclitaxel or capecitabine (n=491)."2.45Analysis of dermatologic events in patients with cancer treated with lapatinib. ( Blackwell, KL; Byrne, JA; Di Leo, A; Gomez, HL; Koch, KM; Koehler, M; Laabs, SM; Lacouture, ME; Preston, AJ; Salazar, VM; Sweetman, RW, 2009)
"To assess the toxicity patterns and effectiveness of doublet chemotherapy when administered at reduced doses of 20% (FOLFOX or FOLFIRI) in combination with anti-EGFR antibodies (cetuximab or panitumumab) in old, vulnerable patients with metastatic colorectal cancer (mCRC)."1.72Reduced-dose of doublet chemotherapy combined with anti-EGFR antibodies in vulnerable older patients with metastatic colorectal cancer: Data from the REVOLT study. ( Aprile, G; Avallone, A; Bilancia, D; Brugnatelli, S; Carlomagno, C; Cicero, G; Cinausero, M; Colombo, A; Corsi, D; Dell'Aquila, E; Pinto, C; Rapisardi, S; Reggiardo, G; Rosati, G, 2022)

Research

Studies (23)

TimeframeStudies, this research(%)All Research%
pre-19901 (4.35)18.7374
1990's1 (4.35)18.2507
2000's5 (21.74)29.6817
2010's13 (56.52)24.3611
2020's3 (13.04)2.80

Authors

AuthorsStudies
Rosati, G1
Corsi, D1
Avallone, A1
Brugnatelli, S1
Dell'Aquila, E1
Cinausero, M1
Aprile, G1
Cicero, G1
Carlomagno, C1
Colombo, A1
Rapisardi, S1
Pinto, C1
Reggiardo, G1
Bilancia, D1
Soueidy, C1
Skaff, S1
Stephan, F1
Kattan, J1
Huang, J1
Jiang, C1
Liu, Z1
Zheng, W1
Zhu, X1
Huang, Z1
Hernandez-Aragues, I1
Baniandrés-Rodríguez, O1
Avilés-Izquierdo, JA1
Vilas-Boas, PT1
Hofheinz, RD1
Lorenzen, S1
Trojan, J1
Ocvirk, J1
Ettrich, TJ1
Al-Batran, SE1
Schulz, H1
Homann, N1
Feustel, HP1
Schatz, M1
Kripp, M1
Schulte, N1
Tetyusheva, M1
Heeger, S1
Vlassak, S1
Merx, K1
Aranda, E1
García-Alfonso, P1
Benavides, M1
Sánchez Ruiz, A1
Guillén-Ponce, C1
Safont, MJ1
Alcaide, J1
Gómez, A1
López, R1
Manzano, JL1
Méndez Ureña, M1
Sastre, J1
Rivera, F1
Grávalos, C1
García, T1
Martín-Valadés, JI1
Falcó, E1
Navalón, M1
González Flores, E1
Ma García Tapiador, A1
Ma López Muñoz, A1
Barrajón, E1
Reboredo, M1
García Teijido, P1
Viudez, A1
Cárdenas, N1
Díaz-Rubio, E1
Que, SKT1
Compton, LA1
Schmults, CD1
Rubovszky, G1
Láng, I1
Ganofszky, E1
Horváth, Z1
Juhos, E1
Nagy, T1
Szabó, E1
Szentirmay, Z1
Budai, B1
Hitre, E1
Dranitsaris, G1
Lacouture, ME2
Piotrowski, MJ1
Gunn, H1
Kirby, J1
Ali, L1
Helm, K1
Schimanski, CC1
Staib, F1
Göhler, T1
Hebart, H1
Heike, M1
Neise, M1
Rudi, J1
Geer, T1
Dingeldein, G1
Lang, C1
Ehscheidt, P1
Flohr, T1
Josten, KM1
Karthaus, M1
Schmittel, A1
Wierecky, J1
Boller, E1
Indorf, M1
Wörns, MA1
Galle, PR1
Moehler, M1
Laabs, SM1
Koehler, M1
Sweetman, RW1
Preston, AJ1
Di Leo, A1
Gomez, HL1
Salazar, VM1
Byrne, JA1
Koch, KM1
Blackwell, KL1
Raoul, JL1
Van Laethem, JL1
Peeters, M1
Brezault, C1
Husseini, F1
Cals, L1
Nippgen, J1
Loos, AH1
Rougier, P1
Seront, E1
Marot, L1
Coche, E1
Gala, JL1
Sempoux, C1
Humblet, Y1
Xiao, YY2
Liu, F2
Chen, ZP2
Ping, QN2
Xu, BH1
Jiang, ZF1
Chua, D1
Shao, ZM1
Luo, RC1
Wang, XJ1
Liu, DG1
Yeo, W1
Yu, SY1
Newstat, B1
Preston, A1
Martin, AM1
Chi, HD1
Wang, L1
Powers, R1
Gordon, R1
Roberts, K1
Kovach, R1
Messersmith, WA1
Laheru, DA1
Senzer, NN1
Donehower, RC1
Grouleff, P1
Rogers, T1
Kelley, SK1
Ramies, DA1
Lum, BL1
Hidalgo, M1
Brennan, DD1
Farrelly, C1
Cooney, R1
Norris, S1
McEniff, N1
Gotlib, V1
Khaled, S1
Lapko, I1
Mar, N1
Saif, MW1
Ueki, H1
Namba, M1
Imoto, S1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Efficacy and Safety of Crisaborole Ointment, a Phosphodiesterase 4 (PDE4) Inhibitor, for the Topical Treatment of Cetuximab-Related Skin Toxicity Among Metastatic Colorectal Cancer Patients:A Prospective, Single-arm, Phase II Clinical Trial[NCT06118047]Phase 233 participants (Anticipated)Interventional2023-08-01Recruiting
Phase-II, Randomized, Multicentre Pilot Study to Evaluate the Safety and Efficacy of the Treatment With mFOLFOX-6 Plus Cetuximab Versus Initial Treatment With mFOLFOX-6 Plus Cetuximab (for 8 Cycles), Followed by Maintenance With Cetuximab Alone as First-l[NCT01161316]Phase 2194 participants (Actual)Interventional2010-08-31Completed
An Open-Label Multicenter Study Administering Lapatinib and Capecitabine (Xeloda) in Women With Advanced or Metastatic Breast Cancer[NCT00508274]Phase 352 participants (Actual)Interventional2007-07-18Terminated (stopped due to Primary analysis was completed in 2015 and data collection post 1-Jul-2019 was not reportable due to local regulations in China.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Clinical Benefit Rate (CBR)

"CBR is defined by the percentage of participants achieving either a confirmed tumor response of complete response (CR) or partial response (PR) or stable disease (SD) for at least 24 weeks. Response Criteria in Solid Tumors (RECIST) is a system for measuring tumor shrinkage or progression in terms of the longest dimensions of the tumor on imaging scans such as computerized tomography (CT). A partial response requires a decrease of 30% or more, complete response requires all target lesions disappear, Progression requires an increase of at least 20%, and Stable disease falls in between these two. All responses have a repeat assessment to confirm the response." (NCT00508274)
Timeframe: Baseline; every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression. The maximum time participants were followed was approx. 90 months

InterventionPercentage of participants (Number)
Lapatinib + Capecitabine57.7

Duration of Response (DOR)

Duration of response (complete response, partial response or stable disease) is defined as the time of first documentation of disease response until the date of disease progression or death due to breast cancer, whichever occurs first. DOR only applied to participants for whom best overall response was complete response (CR), partial response (PR) or stable disease (SD). Participants who had not had a partial response, complete response or stable disease at the cut-off date for this endpoint analysis were censored for duration of response. (NCT00508274)
Timeframe: Baseline; every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression. The maximum time participants were followed was 88.80 months.

InterventionMonths (Median)
Lapatinib + Capecitabine8.18

Progression-Free Survival (PFS)

PFS is defined as the time from first dose date until the date of disease progression or death due to any reason, whichever occurs first. (NCT00508274)
Timeframe: Baseline; every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression. The maximum time participants were followed was 90.38 months.

InterventionMonths (Median)
Lapatinib + Capecitabine6.34

Six Months Progression-Free Survival

Six Months Progression-Free Survival is defined as the percentage of surviving participants who are progression-free longer than six months (greather than 180 days) after the first start date of study treatment. (NCT00508274)
Timeframe: at Baseline and every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression. The maximum time participants were followed up to 90.38 months, with 6 months PFS reported.

InterventionPercentage of participants (Number)
Lapatinib + Capecitabine53.55

Time to Response (TTR)

Time to response is defined as the time from first dose date until first documentation of disease response. TTR only applied to participants for whom best overall response was complete response (CR), partial response (PR) or stable disease (SD). Participants who had not had a partial response, complete response or stable disease at the cut-off date for this endpoint analysis were censored for time to response. (NCT00508274)
Timeframe: Baseline; every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression. The maximum time participants were followed was approx. 14.78 months

InterventionMonths (Median)
Lapatinib + Capecitabine4.07

All Collected Deaths

On treatment deaths were collected from the start of treatment up to 30 days after study drug discontinuation, for a maximum duration of 4276 days (treatment duration ranged from 13 - 4246 days) for Lapatinib and 3384 days (treatment duration ranged form 8 - 3354 days) for Capecitabine. Total deaths was collected from study start to study end (LPLV). (NCT00508274)
Timeframe: up to 4276 days for Lapatinib/up to 3384 days for Capecitabine (on-treatment), approx. 12 years (all collected deaths)

InterventionParticipants (Count of Participants)
Total DeathsOn-treatment Deaths
Lapatinib + Capecitabine112

Number of Participants With Central Nervous System (CNS) as First Site of Relapse

Number of participants who had Central Nervous System metastasis as the first site of relapse. CT, Magnetic Resonance Imaging, etc. were used for the assessment. (NCT00508274)
Timeframe: Baseline; every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression. The maximum time participants were followed was 90 months

Interventionparticipants (Number)
Participants with any site of relapseParticipants with CNS disease as first site of relapse
Lapatinib + Capecitabine172

Reviews

2 reviews available for fluorouracil and Exanthem

ArticleYear
JAAD Grand Rounds quiz: Red-brown hyperkeratotic papules in a 69-year-old man.
    Journal of the American Academy of Dermatology, 2015, Volume: 73, Issue:2

    Topics: Aged; Biopsy, Needle; Disease Progression; Exanthema; Fluorouracil; Follow-Up Studies; Humans; Immun

2015
Analysis of dermatologic events in patients with cancer treated with lapatinib.
    Breast cancer research and treatment, 2009, Volume: 114, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinic

2009

Trials

8 trials available for fluorouracil and Exanthem

ArticleYear
EVITA-a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 04-01, Volume: 29, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuxi

2018
First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study.
    European journal of cancer (Oxford, England : 1990), 2018, Volume: 101

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Diseas

2018
Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study.
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:18

    Topics: Adult; Aged; Anemia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoco

2013
Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine.
    Breast cancer research and treatment, 2014, Volume: 147, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast N

2014
Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care.
    Journal of cancer research and clinical oncology, 2017, Volume: 143, Issue:6

    Topics: Adenocarcinoma; Administration, Cutaneous; Administration, Oral; Adult; Aged; Aged, 80 and over; Ant

2017
Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study.
    BMC cancer, 2009, Apr-14, Volume: 9

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem

2009
Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients.
    Chinese journal of cancer, 2011, Volume: 30, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Capecit

2011
Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Oct-01, Volume: 10, Issue:19

    Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protoc

2004

Other Studies

13 other studies available for fluorouracil and Exanthem

ArticleYear
Reduced-dose of doublet chemotherapy combined with anti-EGFR antibodies in vulnerable older patients with metastatic colorectal cancer: Data from the REVOLT study.
    Journal of geriatric oncology, 2022, Volume: 13, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colonic Neoplasms; Colorectal Neopl

2022
Cetuximab severe cutaneous toxicity… a gateway for bacteremia: case report.
    Anti-cancer drugs, 2023, 01-01, Volume: 34, Issue:1

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Cellulitis; Cetu

2023
Rash and neutropenia after the administration of oxaliplatin and 5-fluorouracil plus calcium folinate injection: a case report.
    Annals of palliative medicine, 2020, Volume: 9, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Exanthema; Fluorouracil; Humans; Leucovorin; Male; M

2020
Cutaneous Drug REactions: Annular, polycyclic erythematous exanthema in an oncology patient.
    European journal of dermatology : EJD, 2017, Jun-01, Volume: 27, Issue:3

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol

2017
Eruptive squamous atypia (also known as eruptive keratoacanthoma): Definition of the disease entity and successful management via intralesional 5-fluorouracil.
    Journal of the American Academy of Dermatology, 2019, Volume: 81, Issue:1

    Topics: Adult; Biopsy, Needle; Carcinoma, Squamous Cell; Cohort Studies; Databases, Factual; Diagnosis, Diff

2019
Successful long-term management of a patient with late-stage metastatic colorectal cancer treated with panitumumab.
    Cancer treatment reviews, 2010, Volume: 36 Suppl 1

    Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemot

2010
[Microemulsion-based gel of fluorouracil for transdermal delivery].
    Yao xue xue bao = Acta pharmaceutica Sinica, 2010, Volume: 45, Issue:11

    Topics: Administration, Cutaneous; Animals; Antimetabolites, Antineoplastic; Dioctyl Sulfosuccinic Acid; Dru

2010
[Water in oil microemulsions containing NaCl for transdermal delivery of fluorouracil].
    Yao xue xue bao = Acta pharmaceutica Sinica, 2011, Volume: 46, Issue:6

    Topics: Administration, Cutaneous; Animals; Antimetabolites, Antineoplastic; Dioctyl Sulfosuccinic Acid; Dru

2011
Symmetrical drug-related intertriginous and flexural exanthema secondary to topical 5-fluorouracil.
    Cutis, 2012, Volume: 89, Issue:5

    Topics: Administration, Cutaneous; Drug Eruptions; Exanthema; Fluorouracil; Hand Dermatoses; Humans; Immunos

2012
Abdominal rash after transarterial chemoembolization via the right inferior phrenic artery.
    Journal of vascular and interventional radiology : JVIR, 2005, Volume: 16, Issue:9

    Topics: Abdomen; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Arteries; Chemoembolization,

2005
Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response.
    Anti-cancer drugs, 2006, Volume: 17, Issue:10

    Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com

2006
[Drug exanthema caused by a new 5-fluorouracil derivative].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 1980, Volume: 31, Issue:4

    Topics: Chemical Phenomena; Chemistry; Exanthema; Female; Fluorouracil; Humans; Middle Aged; Tegafur

1980
Feasibility of adjuvant chemotherapy for breast cancer patients.
    Japanese journal of clinical oncology, 1997, Volume: 27, Issue:5

    Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemo

1997